Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Table 2

Plasma Gal-3 level distribution in study population.

Plasma Gal-3 levels in study population
	Mean	Range (CI 95%)
Nontumoral controls	10.2	8.92-11.5
Adjuvant group
Presurgery	12.8	10.7-14.9
Postsurgery	11.8	9.3-14.2
CTX-1	18.7	15.7- 21.7
CTX-2	29.0	23.6-34.5
CTX-3	36.3	30.6-42.0
CTX-4	19.3	13.9-24.6
Neoadjuvant group
Prechemotherapy	8.47	5.6-11.3
CTX-1	10.86	7.9-13.7
CTX-2	9.62	7.6-11.6
CTX-3	10.38	7.9-12.9
CTX-4	10.90	8.42-13.4

CI: confidence interval; CTX: chemotherapy.